JP2013534908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534908A5 JP2013534908A5 JP2013511636A JP2013511636A JP2013534908A5 JP 2013534908 A5 JP2013534908 A5 JP 2013534908A5 JP 2013511636 A JP2013511636 A JP 2013511636A JP 2013511636 A JP2013511636 A JP 2013511636A JP 2013534908 A5 JP2013534908 A5 JP 2013534908A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- mir
- nucleic acid
- composition
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims 21
- 102000040430 polynucleotide Human genes 0.000 claims 21
- 239000002157 polynucleotide Substances 0.000 claims 21
- 150000007523 nucleic acids Chemical group 0.000 claims 17
- 108091060585 Mir-31 Proteins 0.000 claims 11
- 102000001708 Protein Isoforms Human genes 0.000 claims 11
- 108010029485 Protein Isoforms Proteins 0.000 claims 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims 9
- 102100021262 Frizzled-3 Human genes 0.000 claims 9
- 101000819458 Homo sapiens Frizzled-3 Proteins 0.000 claims 9
- 101001061405 Homo sapiens Frizzled-9 Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 8
- 208000020084 Bone disease Diseases 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 238000009396 hybridization Methods 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 108091070501 miRNA Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 229940122938 MicroRNA inhibitor Drugs 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 108020004688 Small Nuclear RNA Proteins 0.000 claims 2
- 102000039471 Small Nuclear RNA Human genes 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 241000796533 Arna Species 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 claims 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108091060271 Small temporal RNA Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010057469 Vascular stenosis Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- -1 fRNA Proteins 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10163604 | 2010-05-21 | ||
| EP10163604.1 | 2010-05-21 | ||
| PCT/EP2011/058379 WO2011144761A1 (en) | 2010-05-21 | 2011-05-23 | Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534908A JP2013534908A (ja) | 2013-09-09 |
| JP2013534908A5 true JP2013534908A5 (enExample) | 2014-07-10 |
| JP5894581B2 JP5894581B2 (ja) | 2016-03-30 |
Family
ID=44537805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511636A Expired - Fee Related JP5894581B2 (ja) | 2010-05-21 | 2011-05-23 | 骨障害及び/又は心血管障害の治療又は診断に使用する組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20130108687A1 (enExample) |
| EP (1) | EP2571988B1 (enExample) |
| JP (1) | JP5894581B2 (enExample) |
| CN (1) | CN103210085B (enExample) |
| BR (1) | BR112012029656A2 (enExample) |
| CA (1) | CA2800018C (enExample) |
| WO (1) | WO2011144761A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316342A (zh) * | 2013-02-28 | 2013-09-25 | 中国人民解放军沈阳军区总医院 | MiR-31抑制剂用于抑制血管损伤后再狭窄的用途 |
| GB201309882D0 (en) * | 2013-06-03 | 2013-07-17 | Isis Innovation | Prevention and treatment of atrial fibrillation |
| WO2014197747A1 (en) * | 2013-06-05 | 2014-12-11 | The Trustees Of Columbia University In The City Of New York | Exosomes for orofacial diagnostics and therapeutics |
| CN103627705B (zh) * | 2013-10-28 | 2016-02-24 | 南京医科大学 | 与膀胱癌相关的piRNA生物标志物及其应用 |
| WO2015189345A2 (en) * | 2014-06-13 | 2015-12-17 | Universität Für Bodenkultur Wien | Compositions and methods for the diagnosis and treatment of bone fractures and disorders |
| WO2016094406A1 (en) * | 2014-12-08 | 2016-06-16 | Thomas Jefferson University | Treatment and prevention of thrombosis using an anti-mir |
| JP6694240B2 (ja) * | 2015-01-30 | 2020-05-13 | ロート製薬株式会社 | 細胞の品質を評価する方法、及び細胞の品質判定キット |
| CN107176976B (zh) * | 2016-03-11 | 2020-02-14 | 上海交通大学医学院 | 微小rna31前体编码多肽在制备免疫调节药物中的应用 |
| CN107151695B (zh) * | 2016-12-08 | 2021-11-09 | 青岛大学 | 用于检测急性心肌缺血疾病的piRNA组合及其检测方法和应用 |
| CN110129429A (zh) * | 2019-05-22 | 2019-08-16 | 昌乐县人民医院 | 核酸分子在制备诊断骨科疾病的产品中的应用 |
| CN110184270A (zh) * | 2019-05-31 | 2019-08-30 | 固安博健生物技术有限公司 | 非编码rna作为男性骨质疏松症的诊断标志物 |
| CN110055256A (zh) * | 2019-05-31 | 2019-07-26 | 固安博健生物技术有限公司 | Loc105376287作为诊断男性骨质疏松症的分子标志物的用途 |
| CN110951869B (zh) * | 2020-01-02 | 2021-06-18 | 北京市创伤骨科研究所 | 骨质疏松诊治用生物标志物 |
| CN111118139B (zh) * | 2020-01-13 | 2021-06-18 | 北京市创伤骨科研究所 | 一种骨质疏松的分子靶标及其应用 |
| CN111599476B (zh) * | 2020-05-15 | 2023-08-11 | 中南大学湘雅医院 | 一种高血压的预测模型及其建立方法以及用于预测高血压的生物标记物 |
| CN112746101B (zh) * | 2020-12-25 | 2023-02-28 | 深圳市人民医院 | 一种骨质疏松诊断标志物及促进骨质疏松骨再生的核酸药物 |
| CN114426950B (zh) * | 2022-01-25 | 2023-08-04 | 北京大学口腔医学院 | 一种高成骨成血管的血清外泌体及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| EP0943684A3 (en) * | 1998-03-10 | 2002-01-23 | Smithkline Beecham Plc | Frizzled-like polypeptides and polynucleotides |
| US7655785B1 (en) * | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| PT1913952E (pt) * | 2002-12-05 | 2011-04-14 | Univ Arkansas | Determinantes moleculares da doença óssea do mieloma e respectivas utilizações |
| US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| AR043507A1 (es) | 2003-03-14 | 2005-08-03 | Lundbeck & Co As H | Derivados de anilina sustituidos y composiciones farmaceuticas |
| EP1648914A4 (en) * | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| CA2556435C (en) * | 2004-02-13 | 2014-08-12 | The Rockefeller University | Anti-microrna oligonucleotide molecules |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| KR101407707B1 (ko) | 2006-04-03 | 2014-06-19 | 산타리스 팔마 에이/에스 | Anti-mirna 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물 |
| WO2008013963A2 (en) | 2006-07-28 | 2008-01-31 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| US7993831B2 (en) * | 2007-09-14 | 2011-08-09 | Asuragen, Inc. | Methods of normalization in microRNA detection assays |
| US8993509B2 (en) | 2009-03-31 | 2015-03-31 | Robert Zimmerman | Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity |
| US20130210883A1 (en) | 2010-05-21 | 2013-08-15 | Johannes Grillari | Lipase inhibitors |
-
2011
- 2011-05-23 BR BR112012029656A patent/BR112012029656A2/pt not_active Application Discontinuation
- 2011-05-23 EP EP11727134.6A patent/EP2571988B1/en active Active
- 2011-05-23 WO PCT/EP2011/058379 patent/WO2011144761A1/en not_active Ceased
- 2011-05-23 US US13/699,272 patent/US20130108687A1/en not_active Abandoned
- 2011-05-23 CN CN201180034123.1A patent/CN103210085B/zh not_active Expired - Fee Related
- 2011-05-23 JP JP2013511636A patent/JP5894581B2/ja not_active Expired - Fee Related
- 2011-05-23 CA CA2800018A patent/CA2800018C/en active Active
-
2013
- 2013-12-02 US US14/094,772 patent/US9150855B2/en not_active Expired - Fee Related
-
2014
- 2014-12-05 US US14/561,585 patent/US9212362B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534908A5 (enExample) | ||
| Allen et al. | Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle | |
| CN106687602B (zh) | 用于诊断和治疗骨折和骨病的组合物及方法 | |
| DK3134526T3 (en) | LNC RNAs for therapy and diagnosis of cardiac hypertrophy | |
| AU2014284836B2 (en) | Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease | |
| Fiorillo et al. | Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone | |
| JP6919098B2 (ja) | 筋強直性ジストロフィー1型に対するマイクロrnaの変調及びそのためのマイクロrnaのアンタゴニスト | |
| JP2016199565A (ja) | 血管新生、血管形成、若しくは血管修復を促進するか、又は腫瘍血管新生を阻害する方法 | |
| WO2009015071A1 (en) | Screening of micro-rna cluster inhibitor pools | |
| WO2009114681A2 (en) | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy | |
| EA015570B1 (ru) | Фармацевтическая композиция | |
| JP2013523696A5 (enExample) | ||
| JP2010539990A (ja) | アンチセンス転写物を標的とするagRNAおよびギャップマーを用いた遺伝子発現の調節方法 | |
| Philippen et al. | Antisense MicroRNA therapeutics in cardiovascular disease: quo vadis? | |
| Bengestrate et al. | Genome-wide profiling of microRNAs in adipose mesenchymal stem cell differentiation and mouse models of obesity | |
| TW201406774A (zh) | 微rna之mir-15家族之抑制劑 | |
| JP2017528441A5 (enExample) | ||
| KR102547432B1 (ko) | Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| Chang et al. | miR-223 plays a key role in obesogen-enhanced adipogenesis in mesenchymal stem cells and in transgenerational obesity | |
| Gherardi et al. | Transcriptional and epigenetic analyses of the DMD locus reveal novel cis‑acting DNA elements that govern muscle dystrophin expression | |
| JP6928001B2 (ja) | 心臓リモデリングの治療及び診断のためのlncRNA Meg3 | |
| WO2014040742A1 (en) | Treatment of heart disease through modulation of hypoxia-induced erna activity | |
| WO2018047148A1 (en) | Compounds for the inhibition of mirna | |
| Chang et al. | miR-223 Plays A Critical Role in Obesogen-Enhanced Adipogenesis in Mesenchymal Stem Cells and in Transgenerational Obesity | |
| US20230181613A1 (en) | Inhibitors of micro-rna 22 |